Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elbasvir/grazoprevir-based regimens in French adults with chronic hepatitis C virus genotype 4 infection
2016-001159-37Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of elbasvir and grazoprevir in chronic hepatitis C (CHC), sponsored by Merck & Co. Primary endpoints: Proportion of subjects achieving SVR12 and Proportion of treatment-naive F0-F2 subjects achieving SVR12. Started Jun 2017; status: completed.
02
Drugs
elbasvirgrazoprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2016-001159-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001159-37.